The arrival of GLP-1 analog drugs (such as Wegovy) marked a huge shift in the weight-loss drug market. These drugs have been ...

Viking Therapeutics (VKTX) leads the race to win FDA Rx-to-OTC switch for an oral weight loss drug belonging to GLP-1 class ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...

Sometimes diet and exercise are not enough to help the 100 million Americans with obesity lose weight and prevent health ...

Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...

Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...

A new weight loss pill developed by the maker of Ozempic and Wegovy helped ... a GLP-1 receptor agonist that is used to treat ...

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive ...